Related Experiment Video

Updated: Mar 8, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

9.0K

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

Florencia Cayrol1,2, Pannee Praditsuktavorn1, Tharu M Fernando1

  • 1Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine, New York, New York 10065, USA.

Nature Communications
|January 31, 2017
PubMed

Insights

Peripheral T-cell lymphomas (PTCL) are aggressive cancers. Transcription-targeting drug THZ1 shows promise by inhibiting CDK7, offering a new therapeutic strategy for PTCL, especially those with STAT3 mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Peripheral T-cell lymphomas (PTCL) are aggressive hematologic malignancies with limited treatment options and poor prognoses.
  • Current chemotherapy regimens show poor response rates and survival outcomes in PTCL patients.
  • There is an urgent need for novel therapeutic strategies targeting the underlying biology of PTCL.

Purpose of the Study:

  • To investigate the efficacy of transcription-targeting drugs, specifically THZ1, against PTCL.
  • To explore the impact of THZ1 on the STAT signaling pathway in PTCL, including STAT3-mutated cells.
  • To evaluate the combination therapy of THZ1 with BH3 mimetic drugs for improved PTCL treatment.

Main Methods:

  • Treatment of PTCL cells with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).
  • Analysis of STAT signaling pathway activity, STAT3 chromatin binding, and gene expression in response to THZ1.
  • Assessment of PTCL cell sensitivity to BH3 mimetic drugs after THZ1 treatment.
  • Evaluation of combination therapy (THZ1 and obatoclax) in PTCL ex vivo cultures and xenograft models.

Main Results:

  • PTCL cells demonstrate sensitivity to transcription-targeting drugs, particularly THZ1.
  • THZ1 effectively inhibits the STAT signaling pathway, even in PTCL cells with the activating STAT3 Y640F mutation.
  • CDK7 inhibition by THZ1 reduces the expression of key oncogenes (MYC, PIM1, MCL1) and anti-apoptotic proteins (MCL1, BCL-XL).
  • THZ1 sensitizes PTCL cells to BH3 mimetic drugs, leading to improved lymphoma growth control in combination therapy.

Conclusions:

  • THZ1 is a potent inhibitor of PTCL, targeting critical oncogenic pathways.
  • The combination of THZ1 and BH3 mimetics represents a promising targeted therapeutic approach for PTCL patients, including those with STAT3 mutations.
  • This study delineates a potential new agent-based treatment strategy for aggressive PTCL.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K